Thermo Fisher Scientific Inc. (TMO) Position Decreased by Chelsea Counsel Co.

Chelsea Counsel Co. reduced its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 11.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 41,320 shares of the medical research company’s stock after selling 5,370 shares during the quarter. Thermo Fisher Scientific makes up 4.2% of Chelsea Counsel Co.’s holdings, making the stock its 6th largest position. Chelsea Counsel Co.’s holdings in Thermo Fisher Scientific were worth $7,846,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Welch & Forbes LLC increased its position in Thermo Fisher Scientific by 0.3% during the 2nd quarter. Welch & Forbes LLC now owns 12,148 shares of the medical research company’s stock valued at $2,120,000 after buying an additional 34 shares in the last quarter. Korea Investment CORP increased its position in Thermo Fisher Scientific by 6.8% during the 2nd quarter. Korea Investment CORP now owns 483,639 shares of the medical research company’s stock valued at $84,380,000 after buying an additional 30,744 shares in the last quarter. IFP Advisors Inc increased its position in Thermo Fisher Scientific by 3.2% during the 2nd quarter. IFP Advisors Inc now owns 15,402 shares of the medical research company’s stock valued at $2,687,000 after buying an additional 479 shares in the last quarter. Retirement Systems of Alabama increased its position in Thermo Fisher Scientific by 0.4% during the 2nd quarter. Retirement Systems of Alabama now owns 259,285 shares of the medical research company’s stock valued at $45,237,000 after buying an additional 977 shares in the last quarter. Finally, Chicago Partners Investment Group LLC acquired a new position in Thermo Fisher Scientific during the 2nd quarter valued at about $108,000. Hedge funds and other institutional investors own 86.22% of the company’s stock.

A number of research analysts have recently weighed in on TMO shares. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $214.00 price objective on the stock in a report on Thursday, September 14th. Barclays reissued an “overweight” rating and issued a $215.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a report on Monday, September 25th. Goldman Sachs Group started coverage on Thermo Fisher Scientific in a report on Tuesday, September 26th. They issued a “buy” rating and a $225.00 price objective on the stock. Jefferies Group reissued a “hold” rating and issued a $195.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, September 28th. Finally, Leerink Swann increased their price objective on Thermo Fisher Scientific from $190.00 to $207.00 and gave the company an “outperform” rating in a report on Monday, October 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and fifteen have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $212.21.

In related news, CEO Marc N. Casper sold 50,000 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $191.74, for a total transaction of $9,587,000.00. Following the sale, the chief executive officer now directly owns 302,577 shares of the company’s stock, valued at $58,016,113.98. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.49% of the stock is owned by company insiders.

Thermo Fisher Scientific Inc. (NYSE TMO) traded up $2.37 during trading on Friday, reaching $208.66. The company had a trading volume of 1,520,700 shares, compared to its average volume of 1,549,575. The firm has a market capitalization of $83,820.00, a price-to-earnings ratio of 35.43, a price-to-earnings-growth ratio of 1.65 and a beta of 1.06. Thermo Fisher Scientific Inc. has a 12-month low of $140.00 and a 12-month high of $208.72. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.81 and a current ratio of 1.26.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 25th. The medical research company reported $2.31 EPS for the quarter, topping the consensus estimate of $2.24 by $0.07. The firm had revenue of $5.12 billion for the quarter, compared to analyst estimates of $5.03 billion. Thermo Fisher Scientific had a return on equity of 9.09% and a net margin of 10.44%. Thermo Fisher Scientific’s revenue for the quarter was up 13.9% compared to the same quarter last year. During the same period last year, the company earned $2.03 earnings per share. sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 9.36 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Monday, January 15th. Investors of record on Friday, December 15th will be issued a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a yield of 0.29%. The ex-dividend date of this dividend is Thursday, December 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.19%.

COPYRIGHT VIOLATION NOTICE: This report was first published by Stock Observer and is the property of of Stock Observer. If you are accessing this report on another site, it was illegally copied and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be read at https://www.thestockobserver.com/2018/01/12/thermo-fisher-scientific-inc-tmo-position-decreased-by-chelsea-counsel-co.html.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply